Arjo AB (ARJO-B) Fair Value & Analysis
Healthcare · SE · Market cap 7.3B SEK
Fair value as of: Jul 14, 2026
From 23 valuation models · updated 7 days ago
Share price +13.7% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 23.78 – kr 34.51 · fair‑value band kr 21.68 – kr 36.14 · the kr 27.18 price screens below the kr 28.91 fair value. As of Jul 14, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Arjo AB (ARJO-B) currently trades at kr 27.18, while our model-based Fair Value estimate is kr 28.91, implying the stock looks roughly 6.4% fairly valued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Arjo AB generated revenue of 10.8B SEK at a net margin of 3.2%. Revenue declined 5.8% year over year. It earns a return on equity of 4.5%. Net debt stands at 4.5B SEK. Fundamentals as of Jul 14, 2026
Our scenario range runs from kr 21.68 (bear case) to kr 36.14 (bull case); at kr 27.18, the current price sits within that range. The share trades about 24% below its 52-week high and 17% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 16% fair-value upside, at 6%, ARJO-B screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 14, 2026. TTM = trailing twelve months.
About the company
Arjo AB (publ) develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia, Latin America, Africa, and the Pacific. It offers products and solutions for patient handling, hygiene, disinfection, medical beds, pressure injury prevention, diagnostics, hygiene, prevention of pressure injuries and blood clots, and leg ulcer treatment and prevention, as well as for obstetric and cardiac diagnostics. The company also provides dementia care, bariatric room solutions, prone positioning, early mobility, architects and planners, and rehabilitation services, as well as equipment repair and maintenance, and equipment rental and financing solutions. It serves private and public institutions that provide acute and long-term care. Arjo AB (publ) was founded in 1957 and is headquartered in Malmö, Sweden.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Arjo AB reported revenue of kr 11.0B in FY2025 versus kr 9.1B in FY2021, a compound +4.9%/yr. Reported net income was kr 334M in FY2025, compounding −18.1%/yr from FY2021.
Is ARJO-B fairly valued? → Check now
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 14, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation M1CK34 | R$1,022 | R$1,243 | +22% |
| Cencora, Inc COR | $281.24 | $168.24 | -40% |
| Cardinal Health, Inc CAH | $216.30 | $110.75 | -49% |
| Sigma Healthcare Limited SIGGF | $2.15 | $0.6400 | -70% |
| Henry Schein, Inc HSIC | $78.67 | $67.77 | -14% |
| Shanghai Pharmaceuticals Holding 601607 | ¥15.96 | ¥56.73 | +255% |
| Sinopharm Group SHTDY | $10.50 | $28.00 | +167% |
| Galenica AG GALNF | $115.00 | $84.59 | -26% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.69 | ¥25.18 | +16% |
| Medipal Holdings MEPDF | $18.35 | $25.47 | +39% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Arjo AB (ARJO-B) undervalued?
What is the fair value of ARJO-B?
What is the quality score of ARJO-B?
What is the revenue of Arjo AB (ARJO-B)?
What is the net profit margin of ARJO-B?
Does Arjo AB pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Arjo AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.